Trial Condition(s):
Hirsutism, Dermatitis, Seborrheic Alopecia, Severe Acne, Seborrhea
Study on the Prescribing Indications for combinations of cyproterone acetate and ethinylestradiol in 5 European Countries
Bayer Identifier:
17194
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This study is designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers. The primary objective of the study is to characterize the prescribing behaviors for Cyproterone Acetate combined with Ethinyl Estradiol in 5 European countries (Austria, Czech Republic, France, the Netherlands, and Spain), including:
•prescription indications for Cyproterone Acetate combined with Ethinyl Estradiol
•use of Cyproterone Acetate combined with Ethinyl Estradiol in accordance with the updated label
•concomitant use of Cyproterone Acetate combined with Ethinyl Estradiol and combined hormonal contraceptives
•second line treatment with Cyproterone Acetate combined with Ethinyl Estradiol for the indication acne
Inclusion Criteria
- Women who are prescribed CPA/EE medication during the study period. - Women who are willing to participate in the drug utilization study
Exclusion Criteria
- Women who are not willing to sign the informed consent - Women with a language barrier
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations |
|---|
Trial Design
Drug Utilization Study on the Prescribing Indications for CPA/EE in 5 European Countries
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Drug utilization pattern of CPA/EETimeframe: within 6 months
Additional Information
Copyright © Bayer
Powered by
